UK markets closed
  • NIKKEI 225

    29,291.01
    -150.29 (-0.51%)
     
  • HANG SENG

    28,436.84
    -201.69 (-0.70%)
     
  • CRUDE OIL

    72.17
    +0.05 (+0.07%)
     
  • GOLD FUTURES

    1,860.30
    +3.90 (+0.21%)
     
  • DOW

    34,155.88
    -143.45 (-0.42%)
     
  • BTC-GBP

    27,449.19
    -1,280.97 (-4.46%)
     
  • CMC Crypto 200

    956.72
    -35.75 (-3.60%)
     
  • ^IXIC

    14,058.42
    -14.43 (-0.10%)
     
  • ^FTAS

    4,088.47
    +5.27 (+0.13%)
     

Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting

·4-min read

Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous

28-May-2021 / 17:00 GMT/BST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.

Dublin, Ireland - 28 May 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shareholders approved all agenda items at today's virtual annual general meeting of shareholders.

7.227.632 ordinary shares in the capital of Cosmo were represented at this virtual annual general meeting of shareholders constituting 50.29% of the total outstanding ordinary shares in the capital of Cosmo (as of the record date).

About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM) its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Calendar

Jefferies Virtual Healthcare Conference

June 1-4, 2021

Half-Year 2021 Report

July 30, 2021

Investora Conference, Zurich

September 15-16, 2021

Contact
Niall Donnelly, CFO & Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com


End of ad hoc announcement

Language:

English

Company:

Cosmo Pharmaceuticals N.V.

Riverside 2, Sir John Rogerson's

Dublin 2 Dublin

Ireland

Phone:

+ 353 1 817 0370

E-mail:

info@cosmopharma.com

Internet:

https://www.cosmopharma.com/

ISIN:

NL0011832936

Listed:

SIX Swiss Exchange

EQS News ID:

1202273


 

End of Announcement

EQS Group News Service

show this
show this